MEDI0382, a GLP‐1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single‐dose, healthy‐subject, randomized, Phase 1 study
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.13688
Abstract: MEDI0382 is a balanced glucagon‐like peptide‐1/glucagon receptor dual agonist under development for the treatment of type 2 diabetes mellitus and non‐alcoholic steatohepatitis. The primary objective was to assess the safety of MEDI0382 in healthy subjects. read more here.
Keywords: glucagon receptor; receptor dual; dual agonist;